Davies, M., Baldry, E., Bodicoat, D., Chatterjee, S., Edwardson, C., Gray, L., . . . King, J. (2020). The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes [Abstract].
Chicago Style (17th ed.) CitationDavies, Melanie, et al. The SGLT2 Inhibitor Empagliflozin Does Not Stimulate Compensatory Appetite Responses in Patients with Excess Adiposity and Type 2 Diabetes [Abstract]. 2020.
MLA (9th ed.) CitationDavies, Melanie, et al. The SGLT2 Inhibitor Empagliflozin Does Not Stimulate Compensatory Appetite Responses in Patients with Excess Adiposity and Type 2 Diabetes [Abstract]. 2020.
Warning: These citations may not always be 100% accurate.